Second consensus statement on the diagnosis of multiple system atrophy, Neurology, vol.71, issue.9, pp.670-676, 2008. ,
Present and future of disease-modifying therapies in multiple system atrophy, Auton Neurosci, vol.211, pp.31-38, 2018. ,
Multiple system atrophy: insights into a rare and debilitating movement disorder, Nat Rev Neurol, vol.13, issue.4, pp.232-243, 2017. ,
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) ,
, J Neurol Sci, vol.94, issue.1-3, pp.79-100, 1989.
Multiple system atrophy-the nature of the beast, J Neurol Neurosurg Psychiatry, vol.1989, pp.78-89 ,
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neurosci Lett, vol.251, issue.3, pp.205-208, 1998. ,
Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia, J Neural Transm, vol.112, issue.12, pp.1613-1624, 2005. ,
Analyses of copy number and mRNA expression level of the alphasynuclein gene in multiple system atrophy, J Med Dent Sci, vol.55, issue.1, pp.145-153, 2008. ,
Animal models of multiple system atrophy, Neuroscience, vol.211, pp.77-82, 2012. ,
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes, EMBO Rep, vol.3, issue.6, pp.583-588, 2002. ,
Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy, J Neurosci, vol.25, issue.46, pp.10689-10699, 2005. ,
Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration, Neuron, vol.45, issue.6, pp.847-859, 2005. ,
Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci, vol.163, issue.1, pp.94-98, 1999. ,
Differentiation of atypical parkinsonian syndromes with routine MRI, Neurology, vol.54, issue.3, pp.697-702, 2000. ,
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) ,
, Mov Disord, vol.19, issue.12, pp.1391-1402, 2004.
Measuring health-related quality of life in MSA: the MSA-QoL, Mov Disord, vol.22, issue.16, pp.2332-2338, 2007. ,
Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study, Mov Disord, vol.22, issue.8, pp.1138-1144, 2007. ,
Multiple System Atrophy -State of the Art, Curr Neurol Neurosci Rep, vol.17, issue.5, p.41, 2017. ,
Alpha-synuclein mRNA expression in oligodendrocytes in MSA, Glia, vol.62, issue.6, pp.964-970, 2014. ,
Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an in vitro and in vivo Study Using Rodent and Human Models, Stem Cell Reports, 2015. ,
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc Natl Acad Sci U S A, vol.106, issue.31, pp.13010-13015, 2009. ,
Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy, Neuroreport, vol.23, issue.4, pp.259-264, 2012. ,
Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies, PLoS One, vol.7, issue.10, p.46817, 2012. ,
Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, vol.338, issue.6109, pp.949-953, 2012. ,
In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains, Neurobiol Dis, vol.103, pp.101-112, 2017. ,
Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes, J Neurosci, vol.37, issue.49, pp.11835-11853, 2017. ,
alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells, J Clin Invest, vol.121, issue.2, pp.715-725, 2011. ,
Alphasynuclein transfers from neurons to oligodendrocytes, Glia, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01181201
Pathological Endogenous alpha-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy, Stem Cell Reports, vol.10, issue.2, pp.356-365, 2018. ,
alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy, Neurobiol Aging, vol.35, issue.10, pp.2357-2368, 2014. ,
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy, Am J Pathol, vol.171, issue.4, pp.1291-1303, 2007. ,
Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy, Acta Neuropathol Commun, vol.2, p.136, 2014. ,
Endogenous oligodendroglial alpha-synuclein and TPPP/p25alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models, Acta Neuropathol, vol.138, issue.3, pp.415-441, 2019. ,
Evidence for alphasynuclein prions causing multiple system atrophy in humans with parkinsonism, Proc Natl Acad Sci, vol.112, issue.38, pp.5308-5317, 2015. ,
Transmission of multiple system atrophy prions to transgenic mice, Proc Natl Acad Sci U S A, vol.110, issue.48, pp.19555-19560, 2013. ,
MSA prions exhibit remarkable stability and resistance to inactivation, Acta Neuropathol, vol.135, issue.1, pp.49-63, 2018. ,
alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration, Nature, vol.522, issue.7556, pp.340-344, 2015. ,
Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies, Nature, vol.557, issue.7706, pp.558-563, 2018. ,
Comparative analyses of the in vivo induction and transmission of alpha-synuclein pathology in transgenic mice by MSA brain lysate and recombinant alpha-synuclein fibrils, Acta Neuropathol Commun, vol.7, issue.1, p.80, 2019. ,
Is multiple system atrophy an infectious disease?, Ann Neurol, vol.83, issue.1, pp.10-12, 2018. ,
Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy, J Neuropathol Exp Neurol, vol.59, issue.9, pp.830-841, 2000. ,
The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease, J Neurochem, vol.76, issue.1, pp.87-96, 2001. ,
A mouse model of adult-onset multiple system atrophy, Neurobiol Dis, vol.127, pp.339-349, 2019. ,
Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy, Mov Disord, vol.32, issue.8, pp.1230-1239, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01537940
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates, Acta Neuropathol Commun, vol.5, issue.1, p.47, 2017. ,
Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy, Mov Disord, vol.29, issue.3, pp.388-395, 2014. ,
Bladder dysfunction in a transgenic mouse model of multiple system atrophy, Mov Disord, vol.28, issue.3, pp.347-355, 2013. ,
Oligodendroglial alpha-synucleinopathy and MSAlike cardiovascular autonomic failure: experimental evidence, Exp Neurol, vol.247, pp.531-536, 2013. ,
Genome-wide estimate of the heritability of Multiple System Atrophy, Parkinsonism Relat Disord, vol.22, pp.35-41, 2016. ,
Multiple-System Atrophy Research C. Mutations in COQ2 in familial and sporadic multiple-system atrophy, N Engl J Med, vol.87, issue.15, pp.233-244, 2013. ,
Korean Canadian Alliance on Parkinson's D, Related D. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, p.80, 2014. ,
COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese, Mov Disord, vol.30, issue.3, pp.436-437, 2015. ,
Analysis of COQ2 gene in multiple system atrophy, Mol Neurodegener, vol.9, p.44, 2014. ,
Mutational analysis of COQ2 in patients with MSA in Italy, Neurobiol Aging, vol.45, pp.213-211, 2016. ,
Multiple-System Atrophy Brain Bank C. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, p.81, 2014. ,
European Multiple-System Atrophy Study G. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, pp.80-81, 2014. ,
New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy, Neurol Genet, vol.2, issue.2, p.54, 2016. ,
Genetic mutation analysis of the COQ2 gene in Italian patients with multiple system atrophy, Gene, pp.20-144037, 2019. ,
Somatic copy number gains of alpha-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains, Brain, vol.141, issue.8, pp.2419-2431, 2018. ,
LRRK2 exonic variants and risk of multiple system atrophy, Neurology, vol.83, issue.24, pp.2256-2261, 2014. ,
G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy, Mov Disord, vol.22, issue.4, pp.546-549, 2007. ,
Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation, Mov Disord, vol.34, issue.7, pp.1080-1082, 2019. ,
Variants associated with Gaucher disease in multiple system atrophy, Ann Clin Transl Neurol, vol.2, issue.4, pp.417-426, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01122349
Frequency of GBA variants in autopsy-proven multiple system atrophy, Mov Disord Clin Pract, vol.4, issue.4, pp.574-581, 2017. ,
Novel alphasynuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology, Neurobiol Aging, vol.35, issue.9, pp.2180-2181, 2014. ,
alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?, Acta Neuropathol, vol.125, issue.5, pp.753-769, 2013. ,
Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide, Mov Disord, vol.28, issue.9, pp.1184-1199, 2013. ,
A critique of the second consensus criteria for multiple system atrophy, Mov Disord, 2019. ,
Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia, Nat Genet, vol.51, issue.4, pp.649-658, 2019. ,
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry, Mov Disord, vol.25, issue.15, pp.2604-2612, 2010. ,
A validation exercise on the new consensus criteria for multiple system atrophy, Mov Disord, vol.24, issue.15, pp.2272-2276, 2009. ,
When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients, Neurology, vol.85, issue.5, pp.404-412, 2015. ,
Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study, Brain, vol.142, issue.9, pp.2813-2827, 2019. ,
Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients, Brain, vol.125, pp.1070-1083, 2002. ,
Survival of Korean patients with multiple system atrophy, Mov Disord, vol.26, issue.5, pp.909-912, 2011. ,
Clinical features and autonomic testing predict survival in multiple system atrophy, Brain, vol.138, pp.3623-3631, 2015. ,
Natural history of pure autonomic failure: A United States prospective cohort, Ann Neurol, vol.81, issue.2, pp.287-297, 2017. ,
Pure autonomic failure: Predictors of conversion to clinical CNS involvement, Neurology, vol.88, issue.12, pp.1129-1136, 2017. ,
Anhidrosis in multiple system atrophy involves pre-and postganglionic sudomotor dysfunction, Mov Disord, vol.32, issue.3, pp.397-404, 2017. ,
Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy, Acta Neuropathol, vol.113, issue.1, pp.81-86, 2007. ,
Abnormal cardiac [(123)I]-metaiodobenzylguanidine uptake in multiple system atrophy, Mov Disord, vol.25, issue.11, pp.1744-1747, 2010. ,
Postganglionic sudomotor denervation in patients with multiple system atrophy, Neurology, vol.82, issue.24, pp.2223-2229, 2014. ,
Roles of cardiac sympathetic neuroimaging in autonomic medicine, Clin Auton Res, vol.28, issue.4, pp.397-410, 2018. ,
Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy, Mov Disord, vol.30, issue.12, pp.1688-1692, 2015. ,
Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy, Brain, vol.138, pp.2310-2321, 2015. ,
Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group, Mov Disord, vol.29, issue.7, pp.857-867, 2014. ,
Abnormal pain perception in patients with Multiple System Atrophy, Parkinsonism Relat Disord, vol.48, pp.28-33, 2018. ,
Depressive symptoms and life satisfaction in patients with multiple system atrophy, Mov Disord, vol.20, issue.8, pp.951-957, 2005. ,
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy, Parkinsonism Relat Disord, vol.14, issue.8, pp.600-607, 2008. ,
Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism, Parkinsonism Relat Disord, vol.35, pp.36-41, 2017. ,
The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy, BMC Neurol, vol.11, p.157, 2011. ,
Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification, Mov Disord, vol.31, issue.10, pp.1506-1517, 2016. ,
Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism, Neurology, vol.86, issue.13, pp.1242-1249, 2016. ,
Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease, Mov Disord, vol.31, issue.3, pp.325-334, 2016. ,
MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy, Mov Disord, vol.33, issue.4, pp.600-608, 2018. ,
Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis, Mov Disord, vol.34, issue.7, pp.1041-1048, 2019. ,
A totally datadriven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control, Neuroimage Clin, vol.23, p.101858, 2019. ,
Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type, Parkinsonism Relat Disord, vol.63, pp.190-203, 2019. ,
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations, Brain, vol.127, pp.2657-2671, 2004. ,
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis, Lancet Neurol, vol.9, issue.2, pp.149-158, 2010. ,
Abnormal metabolic networks in atypical parkinsonism, Mov Disord, vol.23, issue.5, pp.727-733, 2008. ,
Network correlates of disease severity in multiple system atrophy, Neurology, vol.78, issue.16, pp.1237-1244, 2012. ,
Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study, J Nucl Med, vol.57, issue.1, pp.60-66, 2016. ,
Abnormal metabolic network activity in REM sleep behavior disorder, Neurology, 2014. ,
Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative, Neurobiol Dis, vol.80, pp.29-41, 2015. ,
Natural history of multiple system atrophy in the USA: a prospective cohort study, Lancet Neurol, vol.14, issue.7, pp.710-719, 2015. ,
The natural history of multiple system atrophy: a prospective European cohort study, Lancet Neurol, vol.12, issue.3, pp.264-274, 2013. ,
Survival of patients with pathologically proven multiple system atrophy: a meta-analysis, Neurology, vol.48, issue.2, pp.384-393, 1997. ,
Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, vol.131, pp.1362-1372, 2008. ,
Survival in multiple system atrophy, Mov Disord, vol.23, issue.2, pp.294-296, 2008. ,
Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients, Neuroepidemiology, vol.46, issue.4, pp.261-267, 2016. ,
Multiple system atrophyparkinsonism with slow progression and prolonged survival: a diagnostic catch, Mov Disord, vol.27, issue.9, pp.1186-1190, 2012. ,
Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature, Parkinsonism Relat Disord, vol.24, pp.69-75, 2016. ,
Early stridor onset and stridor treatment predict survival in 136 patients with MSA, Neurology, vol.87, issue.13, pp.1375-1383, 2016. ,
Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH), Clin Auton Res, vol.28, issue.4, pp.355-362, 2018. ,
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial, Lancet Neurol, vol.14, issue.2, pp.145-152, 2015. ,
A randomized trial of mesenchymal stem cells in multiple system atrophy, Ann Neurol, vol.72, issue.1, pp.32-40, 2012. ,
Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE ® PD01A and PD03A: results from the AFF009 phase I trial, Mov Disord, vol.33, issue.2, 2018. ,
Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study, Neuroimage, vol.31, issue.1, pp.240-245, 2006. ,
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy, Brain, vol.129, pp.1040-1049, 2006. ,
Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study, Mov Disord, vol.26, issue.7, pp.1303-1309, 2011. ,
Cerebral atrophy in multiple system atrophy by MRI, J Neurol Sci, vol.173, issue.2, pp.109-112, 2000. ,
Progressive cerebral atrophy in multiple system atrophy, J Neurol Sci, vol.195, issue.2, pp.123-127, 2002. ,
Visualization and quantification of disease progression in multiple system atrophy, Mov Disord, vol.21, issue.10, pp.1674-1681, 2006. ,
Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes, J Neurol, vol.262, issue.8, pp.1876-1882, 2015. ,
Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy, Parkinsonism Relat Disord, vol.20, issue.2, pp.222-225, 2014. ,
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial, Lancet Neurol, vol.18, issue.8, pp.724-735, 2019. ,
Neurofilament light protein in blood predicts regional atrophy in Huntington disease, Neurology, vol.90, issue.8, pp.717-723, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01792038
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis, Neurology, vol.84, issue.22, pp.2247-2257, 2015. ,
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP, Neurology, vol.90, issue.4, pp.273-281, 2018. ,
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy, Ann Clin Transl Neurol, vol.3, issue.3, pp.216-225, 2016. ,
Current Concepts in the Treatment of Multiple System Atrophy, Mov Disord Clin Pract, vol.2, issue.1, pp.6-16, 2015. ,
Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy, Proc Natl Acad Sci, vol.113, issue.34, pp.9593-9598, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01370967
Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy, Mov Disord, vol.34, issue.2, pp.255-263, 2019. ,
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy, Mol Neurodegener, vol.10, p.10, 2015. ,
Combination of alphasynuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy, Acta Neuropathol Commun, vol.5, issue.1, p.2, 2017. ,
The molecular tweezer CLR01 reduces aggregated, pathologic, and seedingcompetent alpha-synuclein in experimental multiple system atrophy, Biochim Biophys Acta Mol Basis Dis, vol.1865, issue.11, p.166513, 2019. ,
A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy, Mol Neurodegener, vol.10, p.48, 2015. ,
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies, JCI Insight, vol.4, issue.16, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02346929
alpha-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy, Acta Neuropathol, vol.132, issue.1, pp.59-75, 2016. ,
Insulin resistance and exendin-4 treatment for multiple system atrophy, Brain, vol.140, issue.5, pp.1420-1436, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01537233
Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy ,
, Mol Neurodegener, vol.12, issue.1, p.52, 2017.
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy, Neurotherapeutics, vol.13, issue.4, pp.871-879, 2016. ,
Translational therapies for multiple system atrophy: Bottlenecks and future directions, Auton Neurosci, vol.211, pp.7-14, 2018. ,
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial), Mov Disord, vol.25, issue.1, pp.97-107, 2010. ,
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study, Brain, vol.132, pp.156-171, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00603311
Efficacy and safety of rifampicin for multiple system atrophy: a randomised, doubleblind, placebo-controlled trial, Lancet Neurol, vol.13, issue.3, pp.268-275, 2014. ,
Safety, biomarker effects, and efficacy of the myeloperoxidase inhibitor AZD3241in patients with multiple system atrophy: a 12-week randomized multicenter PET study, Clin Auton Res, vol.28, p.144, 2018. ,
Preliminary results of the French MSA fluoxetine study, Eur J Neurol, vol.19, issue.1, p.262, 2012. ,
Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy, Neurology, vol.93, issue.1, pp.77-87, 2019. ,
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results, Mov Disord, vol.23, issue.15, pp.2129-2170, 2008. ,
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting, Neurology, vol.90, issue.2, pp.74-82, 2018. ,
Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies, Neurobiol Dis, vol.67, pp.133-139, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01217333
Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations, Lancet Neurol, vol.14, issue.8, pp.855-866, 2015. ,